ALLAN E RUBENSTEIN, MD
Neurology at 32 St, New York, NY
License number
New York 112534
Category
Neurology
Type
Neurology
Address
Address
160 E 32Nd St FLOOR 2ND, New York, NY 10016
Phone
(212) 264-9695
(212) 974-1042 (Fax)
(212) 974-1042 (Fax)
Personal information
See more information about ALLAN E RUBENSTEIN at radaris.comName
Address
Phone
15 W 81St St #4G, New York, NY 10024
15 W 81St St, New York, NY 10024
225 Central Park W APT 902, New York, NY 10024
604 Verbank Rd, Millbrook, NY 12545
Huntington, NY
Organization information
See more information about ALLAN E RUBENSTEIN at bizstanding.comAllan E Rubenstein MD
160 E 32 St #2, New York, NY 10016
Categories:
Neurology Physicians & Surgeons
Phone:
(212) 652-1900 (Phone)
Professional information
Vice Chairman And Lead Director At The Cooper Companies
Position:
Clinical Professor of Neurology at NYU Medical Center, Vice Chairman and Lead Director at The Cooper Companies
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
NYU Medical Center
since Jan 2009
-
Clinical Professor of Neurology
The Cooper Companies
since 1992
-
Vice Chairman and Lead Director
NexGenix Pharmaceuticals
Jun 2003 - Jun 2011
-
CEO
Education:
Tufts University School of Medicine 1968 - 1970
Doctor of Medicine (MD) University of Rochester School of Medicine and Dentistry 1966 - 1968
Doctor of Medicine (MD) University of Rochester School of Medicine and Dentistry 1966 - 1968
Skills:
Drug Discovery, Lifesciences, Biotechnology, Clinical Trials, Pharmaceutical Industry, Cancer, Oncology, Molecular Biology, Cell Biology, Biochemistry, Healthcare, Immunology, Medical Devices, GLP, FDA
Languages:
French
Dr. Allan E Rubenstein, New York NY - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
Neurofibromatosis Clinic
160 E 32Nd St SUITE L3, New York 10016
(212) 263-9695 (Phone)
160 E 32Nd St SUITE L3, New York 10016
(212) 263-9695 (Phone)
Certifications:
Neurology, 1976
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Neurofibromatosis Clinic
160 E 32Nd St SUITE L3, New York 10016
NYU Langone Medical Center
550 1St Ave, New York 10016
160 E 32Nd St SUITE L3, New York 10016
NYU Langone Medical Center
550 1St Ave, New York 10016
Education:
Medical School
Tufts University
Graduated: 1970
Harlem Hospital
Columbia Presby Med Center
Tufts University
Graduated: 1970
Harlem Hospital
Columbia Presby Med Center
Allan E Rubenstein, New York NY
Specialties:
Neurology, Internal Medicine
Work:
Comp Neurology Serv Pc
152 W 57Th St, New York, NY 10019
152 W 57Th St, New York, NY 10019
Education:
Tufts University (1970)
Treatment Of Neurofibromatosis With Radicicol And Its Derivatives
US Patent:
8329683, Dec 11, 2012
Filed:
Dec 4, 2009
Appl. No.:
12/631667
Inventors:
Ruihong Chen - Foster City CA, US
Allan E. Rubenstein - New York NY, US
Jin-Chen Yu - Palo Alto CA, US
Nicolas Winssinger - Strasbourg, FR
Sofia Barluenga - Strasbourg, FR
Allan E. Rubenstein - New York NY, US
Jin-Chen Yu - Palo Alto CA, US
Nicolas Winssinger - Strasbourg, FR
Sofia Barluenga - Strasbourg, FR
Assignee:
Nexgenix Pharmaceuticals, LLC - New York NY
Universite de Strasbourg - Strasbourg
Universite de Strasbourg - Strasbourg
International Classification:
A61K 31/33
US Classification:
514183
Abstract:
The present invention provides compounds of formulae Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va and the therapeutic use thereof. The present invention also includes methods of treating NF2-deficient or NF1-deficient cells or neurodegenerative diseases with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va. Furthermore, the present invention is directed to methods of inhibiting the growth of NF2-deficient or NF1-deficient tumors. The methods comprise contacting NF2-deficient or NF1-deficient tumor cells with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va. The present invention is also directed to the combinational use of radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va with at least one additional active agent, such as one or more HSP90 inhibitors.
Local Treatment Of Neurofibromas
US Patent:
8487004, Jul 16, 2013
Filed:
Jun 15, 2012
Appl. No.:
13/524590
Inventors:
Ruihong Chen - Foster City CA, US
Allan E. Rubenstein - New York NY, US
Xiaodong Shen - Foster City CA, US
Scott Stewart - La Jolla CA, US
Jin-Chen Yu - Palo Alto CA, US
Allan E. Rubenstein - New York NY, US
Xiaodong Shen - Foster City CA, US
Scott Stewart - La Jolla CA, US
Jin-Chen Yu - Palo Alto CA, US
Assignee:
Nexgenix Pharmaceuticals, Inc. - New York NY
International Classification:
A01N 37/12, A01N 37/44, A01N 37/10, A01N 47/28, A61K 31/195, A61K 37/17
US Classification:
514567, 514597
Abstract:
A method for treating a neurofibroma, e. g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.
Local Treatment Of Neurofibromas
US Patent:
2009011, May 7, 2009
Filed:
Feb 2, 2006
Appl. No.:
11/815443
Inventors:
Ruihong Chen - Foster City CA, US
Allan E. Rubenstein - New York NY, US
Xiaodong Shen - Foster City CA, US
Scott Stewart - San Diego CA, US
Jin-Chen Yu - Palo Alto CA, US
Allan E. Rubenstein - New York NY, US
Xiaodong Shen - Foster City CA, US
Scott Stewart - San Diego CA, US
Jin-Chen Yu - Palo Alto CA, US
International Classification:
A61K 31/65, A61K 31/165
US Classification:
514152, 514154, 514567
Abstract:
A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.
Macrocyclic Prodrug Compounds Useful As Therapeutics
US Patent:
2011019, Aug 4, 2011
Filed:
Aug 23, 2010
Appl. No.:
12/861806
Inventors:
James Heck - New York NY, US
Nicolas Winssinger - Strasbourg, FR
John C. Chabala - Scotch Plains NJ, US
Sofia Barluenga - Strasbourg, FR
Ruihong Chen - Foster City CA, US
Allan Rubenstein - New York NY, US
Jin-Chen Yu - Palo Alto CA, US
Nicolas Winssinger - Strasbourg, FR
John C. Chabala - Scotch Plains NJ, US
Sofia Barluenga - Strasbourg, FR
Ruihong Chen - Foster City CA, US
Allan Rubenstein - New York NY, US
Jin-Chen Yu - Palo Alto CA, US
Assignee:
NEXGENIX PHARMACEUTICALS - New York NY
UNIVERSITE DE STRASBOURG - Strasbourg
UNIVERSITE DE STRASBOURG - Strasbourg
International Classification:
A61K 31/675, C07F 9/58, C07F 9/59, A61P 9/00, A61P 29/00, A61P 35/00, A61P 25/00, A61P 11/06, C12N 5/09
US Classification:
514 89, 546 22, 435325, 435350, 435353, 435354, 435366
Abstract:
The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, an inflammatory disease, a neurological or neurodegenerative disease, cancer, a cardiovascular disease, allergy, asthma, a hormone-related disease, and tumors or symptoms resulting from neurofibromatosis.
Local Treatment Of Neurofibromas
US Patent:
2013034, Dec 26, 2013
Filed:
Jun 14, 2013
Appl. No.:
13/918223
Inventors:
Allan E. Rubenstein - New York NY, US
Xiadong Shen - Foster City CA, US
Scott Stewart - San Diego CA, US
Jin-Chen Yu - Palo Alto CA, US
Xiadong Shen - Foster City CA, US
Scott Stewart - San Diego CA, US
Jin-Chen Yu - Palo Alto CA, US
International Classification:
A61K 31/513, A61K 31/4745
US Classification:
514274, 514293
Abstract:
A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.